Pfizer, Haleon
Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon -- Update
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $29.09 which represents a slight increase of $0.12 or 0.41% from the prior close of $28.97. The stock opened at $29.02 and ...
Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...
4d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback